49 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Design and synthesis of a novel series of [1-(4-hydroxy-benzyl)-1H-indol-5-yloxy]-acetic acid compounds as potent, selective, thyroid hormone receptorß agonists.
Eli Lilly
Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORß and ROR¿t.
Phenex Pharmaceuticals
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptorß agonist in clinical trials for the treatment of dyslipidemia.
Madrigal Pharmaceuticals
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptorß agonists.
Sanwa Kagaku Kenkyusho
Development of novel Vitamin D Receptor-Coactivator Inhibitors.
University of Wisconsin-Milwaukee
Synthesis and evaluation of methylsulfonylnitrobenzamides (MSNBAs) as inhibitors of the thyroid hormone receptor-coactivator interaction.
St. Jude Children'S Research Hospital
Identification of Potent and Selective Diphenylpropanamide ROR? Inhibitors.
New York University School of Medicine
Design, synthesis, and structure-activity relationship (SAR) of N-[7-(4-hydroxyphenoxy)-6-methylindan-4-yl]malonamic acids as thyroid hormone receptorß (TRß) selective agonists.
Kissei Pharmaceutical
Selective thyromimetics using receptor and tissue selectivity approaches: prospects for dyslipidemia.
Zydus Research Centre
Synthesis and evaluation of sulfonylnitrophenylthiazoles (SNPTs) as thyroid hormone receptor-coactivator interaction inhibitors.
Institut Pasteur Korea
Discovery of novel indane derivatives as liver-selective thyroid hormone receptorß (TRß) agonists for the treatment of dyslipidemia.
Kissei Pharmaceutical
Characterization of thyroid hormone receptor alpha (TRalpha)-specific analogs with varying inner- and outer-ring substituents.
University of California San Francisco
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes.
Abbott Laboratories
Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.
Phenex Pharmaceuticals
Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors.
St. Jude Children'S Hospital
Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs.
Metabasis Therapeutics
Design and synthesis of novel 3-hydroxy-cyclobut-3-ene-1,2-dione derivatives as thyroid hormone receptor beta (TR-beta) selective ligands.
Zydus Research Centre
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
Metabasis Therapeutics
Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor ? Agonist.
Guangzhou Institutes of Biomedicine and Health
Thyroid receptor ligands. Part 5: novel bicyclic agonist ligands selective for the thyroid hormone receptor beta.
Karo Bio
A new class of high affinity thyromimetics containing a phenyl-naphthylene core.
Pharmaceutical Research Institute
Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics.
Pfizer
Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment.
University of California
Design, synthesis and biological evaluation of novel TR? selective agonists sustained by ADME-toxicity analysis.
University of Pisa
Discovery of 3?,7?,11?-Trihydroxy-6?-ethyl-5?-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
Tes Pharma
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
Karo Bio
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPAR?.
Goethe-University Frankfurt
Discovery of potent and selective PPAR?/? dual antagonists and initial biological studies.
Inception Sciences
DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties.
Purdue Pharma Discovery Research
WAY-855 (3-amino-tricyclo[2.2.1.02.6]heptane-1,3-dicarboxylic acid): a novel, EAAT2-preferring, nonsubstrate inhibitor of high-affinity glutamate uptake.
Wyeth Research